Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo
/in Dendritic Cells, International Publications /von 2005-08-23 / Blood 2005 Dec;106(13):4225-33Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-08-01 / Clin. Cancer Res. 2005 Aug;11(15):5515-25Natural-killer cells and dendritic cells: „l’union fait la force“
/in Dendritic Cells, International Publications /von 2005-06-02 / Blood 2005 Oct;106(7):2252-8Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-06-01 / Clin. Cancer Res. 2005 Jun;11(11):4160-7Chaperone-rich cell lysates, immune activation and tumor vaccination
/in Dendritic Cells, Hyperthermia, International Publications /von 2005-05-11 / Cancer Immunol. Immunother. 2006 Mar;55(3):329-38Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function
/in Dendritic Cells, Hyperthermia, International Publications /von 2005-04-28 / Cancer Immunol. Immunother. 2006 Mar;55(3):292-8Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity
/in Dendritic Cells, International Publications /von 2005-04-04 / J. Leukoc. Biol. 2005 Aug;78(2):319-24Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-04-01 / J. Neurooncol. 2005 Apr;72(2):107-13Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-77IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de